Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTI-621 in Relapsed/Refractory Hematologic Malignancies and Solid Tumors
NCT02663518Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Jan 2016
- Primary completion
- Nov 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, open-label trial of ontorpacept in lymphoma, chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and 7 more (16 arms), sponsored by Pfizer. Primary endpoints: Treatment Emergent Adverse Events and Dose Limiting Toxicities. Started Jan 2016; status: terminated.
02
Drugs
ontorpacept
03
Conditions
lymphomachronic lymphocytic leukemia (CLL)multiple myeloma (MM)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02663518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02663518.